Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients
Open Access
- 1 January 2023
- journal article
- review article
- Published by Touch Medical Media, Ltd. in Infectious Diseases
- Vol. 2 (1) , 31
Abstract
For people with HIV/hepatitis B virus (HBV) co-infection who develop comorbidities that require polypharmacy, treatment may be complicated due to drug interactions and overlapping toxicities of medications received. As the population with HIV ages, there are more patients developing malignancies and undergoing transplantation, and management can be complicated. This review describes the best strategies for the treatment of a hypothetical patient with HIV/HBV co-infection who develops diffuse large B-cell lymphoma and ultimately undergoes autologous haematopoietic stem cell transplantation. In this theoretical case, the patient is treated with bictegravir/emtricitabine/tenofovir alafenamide. Situations arise where people with HIV have underlying antiretroviral drug resistance and HBV drug resistance that require optimization of their antiviral therapy. As these types of cases are seen commonly at our institution, we discuss special situations that develop during treatment, including immune reconstitution inflammatory syndrome, that require close monitoring and occasional treatment modifications during their course of therapy.Keywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 50 references indexed in Scilit:
- Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruptionAIDS, 2010
- Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2007
- The HBV Drug Entecavir — Effects on HIV-1 Replication and ResistanceNew England Journal of Medicine, 2007
- An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individualsAIDS, 2003
- Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/Hepatitis B Virus–Coinfected Individuals for Whom Interferon‐α and Lamivudine Therapy Have FailedThe Journal of Infectious Diseases, 2002
- Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudineAIDS, 2002
- Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replicationHepatology, 2002
- Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC)Journal of Virology, 2001
- Chronic Active Hepatitis B Exacerbations in Human Immunodeficiency Virus‐Infected Patients Following Development of Resistance to or Withdrawal of LamivudineClinical Infectious Diseases, 1999